206 SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib

Osimertinib, a potent, third-generation, oral EGFR-TKI is the preferred first-line treatment in EGFRm advanced NSCLC. However, tumours eventually develop resistance and METoverexpression and/or amplification is the most common acquired resistance mechanism. Savolitinib is an oral, potent, and highly selective MET-TKI. Savolitinib +osimertinib has been investigated in the Ph1B TATTON (NCT02143466)/Ph2 SAVANNAH (NCT03778229) studies. SAFFRON (NCT05261399) aims to assess efficacy/safety of savolitinib+osimertinib vs platinum-based chemotherapy in adult patients with EGFRm, MET-overexpressed and/or -amplified, locally advanced/metastatic NSCLC, with progressive disease (PD) on osimertinib.